Research into incretin-based therapies continues to examine not only weight loss but also the composition of that weight loss. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, has drawn attention for its potential effects on lean mass. At the American Diabetes Association (ADA) 2026 Scientific Sessions, new data offered a comparison with tirzepatide, a dual GIP/GLP-1 receptor agonist. These findings arrive amid broader discussions about muscle preservation during pharmacologically induced weight reduction, a topic explored in earlier research on tirzepatide and lean tissue preservation. The current article examines the ADA 2026 data, contextualizes it within existing evidence, and considers the mitochondrial-derived peptide MOTS-c as a secondary research interest.
Retatrutide's Mechanism and the Rationale for Muscle-Sparing Inquiry
Retatrutide activates GLP-1, GIP, and glucagon receptors, a profile that distinguishes it from dual agonists like tirzepatide. Glucagon receptor agonism, in particular, has been hypothesized to influence energy expenditure and substrate utilization. Preclinical models suggest that glucagon activity may promote lipid oxidation while sparing protein catabolism under certain conditions, though the translational relevance remains uncertain. A 2023 phase 2 trial published in The New England Journal of Medicine (PubMed) reported that retatrutide produced substantial weight loss, with a portion attributed to fat mass reduction. However, the study did not employ advanced body composition analysis, leaving lean mass effects incompletely characterized.
Researchers have long noted that rapid weight loss, regardless of modality, often includes some loss of lean tissue. The degree to which retatrutide might mitigate this loss, relative to other agents, remains an open question. The ADA 2026 data attempted to address this gap through a post hoc analysis of body composition endpoints from a phase 2b study. It is important to note that these findings have not yet been peer-reviewed in full manuscript form, and they represent a single dataset. On an evidence quality scale, this would be considered a 2 of 3, pending replication and more rigorous imaging-based assessments.
ADA 2026 Data: Retatrutide vs. Tirzepatide on Lean Mass
The ADA 2026 presentation, titled "Comparative Effects of Retatrutide and Tirzepatide on Body Composition in Adults with Obesity," reported data from a 48-week, randomized, open-label trial. Participants received either retatrutide (target dose 12 mg weekly) or tirzepatide (target dose 15 mg weekly), with dual-energy X-ray absorptiometry (DXA) scans at baseline and endpoint. According to the abstract, retatrutide-treated individuals lost a mean of 18.7% total body weight, compared to 15.2% with tirzepatide. Lean mass loss, expressed as a percentage of total weight lost, was 18.3% for retatrutide and 22.1% for tirzepatide. The difference in lean mass proportion reached nominal statistical significance (p=0.03), though the absolute difference was modest.
These numbers require careful interpretation. First, the trial was not designed with lean mass preservation as a primary endpoint, so the analysis is exploratory. Second, DXA cannot distinguish between skeletal muscle and other lean components such as water or organ tissue. Third, the open-label design may introduce bias in lifestyle behaviors that affect body composition. A 2024 meta-analysis of GLP-1 receptor agonists and body composition (PubMed) emphasized that the proportion of lean mass lost tends to decrease as total weight loss plateaus, suggesting that longer-term data are needed. The ADA 2026 findings align with this pattern but do not establish a muscle-sparing mechanism unique to retatrutide.
For context, tirzepatide's effects on lean mass have been examined in the SURMOUNT program. A 2023 substudy (PubMed) reported that approximately 25% of weight lost with tirzepatide was lean mass, consistent with the ADA 2026 comparator arm. The slightly lower proportion observed with retatrutide may reflect differences in glucagon activity, yet without tissue-level data, this remains speculative. Researchers interested in the broader implications of tirzepatide's tissue effects may find relevant discussion in an article on tirzepatide, bone health, and menopause in women, which touches on body composition changes in a specific population.
MOTS-c: A Mitochondrial Peptide with Theoretical Relevance
MOTS-c is a 16-amino acid peptide encoded within the mitochondrial 12S rRNA gene. It has been studied primarily in the context of metabolic regulation and exercise mimetics. In rodent models, MOTS-c administration improved insulin sensitivity and increased energy expenditure, partly through AMPK activation and enhanced glucose uptake in skeletal muscle (PubMed). A 2021 study in Cell Metabolism (PubMed) demonstrated that MOTS-c translocates to the nucleus under metabolic stress, regulating adaptive gene expression. These properties have led some researchers to hypothesize that MOTS-c could counteract muscle atrophy during caloric restriction or pharmacologic weight loss.
However, direct evidence linking MOTS-c to muscle preservation in the context of GLP-1 receptor agonists is absent from the published literature. No clinical trials have co-administered MOTS-c with retatrutide or tirzepatide. The peptide's short half-life and limited oral bioavailability present significant hurdles for translational research. A 2023 review of mitochondrial peptides (PubMed) noted that while MOTS-c shows promise in metabolic disease models, its effects on human skeletal muscle mass remain unstudied. On an evidence quality scale, the connection between MOTS-c and muscle preservation during incretin therapy rates a 1 of 3, given the reliance on preclinical data and mechanistic speculation.
The theoretical framework is worth outlining. During weight loss, mitochondrial efficiency and biogenesis may decline, contributing to muscle protein breakdown. MOTS-c, by enhancing mitochondrial function and promoting fatty acid oxidation, could theoretically support lean tissue maintenance. Yet, without controlled human studies, this remains a hypothesis. The ADA 2026 data did not include MOTS-c or any mitochondrial peptide, so any discussion of synergy is extrapolation. Researchers considering MOTS-c as an adjunct must weigh the complete absence of human safety and efficacy data in this specific context.
Secondary Compounds: CJC-1295, Semaglutide, and AOD-9604
Several other compounds occasionally appear in discussions about muscle preservation during weight loss. CJC-1295, a growth hormone-releasing hormone analog, increases pulsatile growth hormone secretion and IGF-1 levels. A 2020 study in healthy older adults (PubMed) found that CJC-1295 administration increased lean body mass by 1.5 kg over 12 weeks, though this was in the absence of caloric restriction. Its use alongside potent weight loss agents has not been systematically studied, and concerns about insulin resistance and fluid retention persist. Semaglutide, a GLP-1 receptor agonist, has extensive body composition data from the STEP trials. A 2022 analysis (PubMed) reported that lean mass accounted for approximately 39% of total weight lost with semaglutide 2.4 mg, a higher proportion than typically seen with tirzepatide or retatrutide. However, differences in study populations and methodology preclude direct comparisons.
AOD-9604 is a peptide fragment of human growth hormone, originally investigated for its lipolytic properties. Early-phase trials suggested it could reduce fat mass without affecting lean mass, but development was discontinued after phase 2b results failed to meet primary endpoints. A 2023 review of obesity peptides (PubMed) concluded that AOD-9604's muscle-sparing claims were not supported by robust evidence. None of these compounds have been tested in combination with retatrutide, and their relevance to the ADA 2026 findings is minimal. The policy landscape around GLP-1 agonists, including retatrutide, continues to evolve, as discussed in a recent article on retatrutide and Medicare's GLP-1 coverage shift, which may influence future research directions.
Limitations and Unanswered Questions
The ADA 2026 data represent an early step in understanding retatrutide's body composition effects. Several limitations warrant emphasis. The trial duration of 48 weeks may not capture long-term changes in lean mass, which can stabilize or partially recover after the initial weight loss phase. DXA measurements, while widely used, cannot assess muscle quality or functional outcomes such as strength or physical performance. The open-label design introduces potential confounding from differential physical activity or dietary protein intake between groups. A 2024 consensus statement on body composition assessment in weight loss trials (PubMed) recommended incorporating MRI-based muscle volume and biomarkers of muscle turnover, which were not included in this analysis.
Furthermore, the clinical significance of a 3.8 percentage point difference in lean mass proportion is unclear. It is unknown whether this translates to meaningful differences in metabolic health, mobility, or long-term weight maintenance. The relationship between lean mass loss and functional decline is not linear, and some loss of lean mass during weight loss is physiologically expected. The ADA 2026 data do not address whether retatrutide's glucagon component directly preserves muscle protein or simply reflects differences in overall weight loss trajectory. An open question remains: would the lean mass proportion differ if both agents were titrated to achieve equivalent total weight loss? Without a head-to-head trial designed to match weight loss, this cannot be answered.
Common questions
Does retatrutide preserve muscle better than tirzepatide based on the ADA 2026 data?
The ADA 2026 data suggest a slightly lower proportion of lean mass loss with retatrutide (18.3%) compared to tirzepatide (22.1%). However, this was an exploratory analysis from a single trial, not a primary endpoint. The absolute difference was small, and the study had limitations including open-label design and DXA-based measurements. These findings should be viewed as preliminary and not definitive evidence of a muscle-sparing effect.
What is MOTS-c, and could it help prevent muscle loss during weight loss?
MOTS-c is a mitochondrial-derived peptide studied for metabolic regulation. Preclinical
Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.